Form 4: Bristol-Myers Squibb Executive Samit Hirawat Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Samit Hirawat, EVP, Chief Medical Officer, Drug Development at Bristol-Myers Squibb, reports transactions involving common stock and market share/performance units, including vesting, adjustments, and shares withheld for taxes.
Summary
- On March 10, 2024, Samit Hirawat, an executive at Bristol-Myers Squibb, reported changes in beneficial ownership of company stock.
- These changes involve common stock, market share units, and performance shares.
- Transactions included the vesting of market share units granted in 2020 and 2021, as well as the distribution of performance shares earned under the 2021-2023 Long-Term Performance Award.
- Adjustments were made to the number of shares acquired upon vesting of market share units due to performance factors.
- Shares were also withheld for payment of taxes upon vesting of awards.
- Some market share units granted in 2022 and 2023 were cancelled because the minimum payout factor of 80% was not achieved.
- Hirawat directly owns 60,279 shares of common stock after the reported transactions.
- Hirawat directly owns 40,635 Market Share Units that will vest in 2028.
- Hirawat directly owns 60,952 Performance Shares that will vest in 2027.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The report primarily details routine transactions related to executive compensation. The cancellation of some market share units is a minor negative, but overall, the document reflects standard corporate governance procedures.
Positives
- The vesting of market share units and distribution of performance shares indicate that certain performance targets were met, at least partially, for the periods covered by those awards.
Negatives
- The cancellation of market share units granted in 2022 and 2023 suggests that the company did not achieve the minimum performance threshold (80% payout factor) for those specific grants.
Risks
- Future performance may not meet the targets required for full vesting of market share units and performance shares, potentially impacting executive compensation.
- Changes in the company's stock price could affect the value of market share units, as the payout factor is tied to the stock's performance.
Future Outlook
The document indicates future vesting dates for market share units and distribution dates for performance shares, contingent on continued employment and potentially on the achievement of specific performance targets.
Industry Context
Executive compensation through equity-based awards is a common practice in the pharmaceutical industry to align management's interests with those of shareholders. The use of market share units and performance shares ties compensation to both the company's stock performance and its overall strategic goals.
Comparison to Industry Standards
- Companies like Pfizer (PFE), Merck (MRK), and Johnson & Johnson (JNJ) also utilize equity-based compensation, including stock options, restricted stock units (RSUs), and performance-based awards.
- The specific metrics and payout factors for performance-based awards vary across companies, but they generally focus on financial performance (e.g., revenue growth, earnings per share) and strategic objectives (e.g., drug development milestones, market share gains).
- The vesting schedules and performance criteria for Bristol-Myers Squibb's market share units and performance shares appear to be fairly standard within the industry.
Stakeholder Impact
- The vesting of equity-based awards can have a positive impact on employee morale and motivation.
- Shareholders may view these awards as a way to align management's interests with their own.
- The cancellation of some market share units could be seen as a sign of underperformance, potentially impacting investor sentiment.
Next Steps
- Continued monitoring of the company's stock performance and achievement of performance targets will be necessary to determine the ultimate value of the market share units and performance shares.
- Future Form 4 filings will likely report additional transactions related to these equity-based awards.
Key Dates
| Date | Description |
|---|---|
| 03/10/2020 | Grant date of market share units, one-quarter of which vested on 03/10/2024. |
| 03/10/2021 | Grant date of market share units, one-quarter of which vested on 03/10/2024. |
| 03/10/2022 | Grant date of market share units, one-quarter of which were cancelled on 03/10/2024 due to not meeting the minimum payout factor. |
| 03/10/2023 | Grant date of market share units, one-quarter of which were cancelled on 03/10/2024 due to not meeting the minimum payout factor. |
| 03/10/2024 | Date of the reported transactions, including vesting of market share units, distribution of performance shares, and shares withheld for taxes. |
| 03/12/2024 | Date of signature of the report. |
| 03/10/2025 | Vesting date for market share units granted on March 10, 2021. |
| 03/10/2026 | Vesting date for market share units granted on March 10, 2022. |
| 03/10/2027 | Distribution date for performance shares. |
| 03/10/2028 | Vesting date for market share units granted on March 10, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.